Swiss National Bank Invests $546,000 in LENZ Therapeutics, Inc. (NASDAQ:LENZ)

Swiss National Bank bought a new stake in LENZ Therapeutics, Inc. (NASDAQ:LENZ) in the 4th quarter, Holdings Channel reports. The firm bought 18,900 shares of the company’s stock, valued at approximately $546,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Harbor Capital Advisors Inc. acquired a new position in LENZ Therapeutics in the 4th quarter valued at about $1,270,000. Parkman Healthcare Partners LLC bought a new stake in shares of LENZ Therapeutics in the third quarter valued at approximately $3,308,000. Barclays PLC grew its position in LENZ Therapeutics by 273.1% during the third quarter. Barclays PLC now owns 16,463 shares of the company’s stock worth $391,000 after buying an additional 12,051 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new position in LENZ Therapeutics in the third quarter valued at about $743,000. Finally, Charles Schwab Investment Management Inc. raised its position in LENZ Therapeutics by 197.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 123,371 shares of the company’s stock valued at $2,929,000 after purchasing an additional 81,901 shares in the last quarter. Institutional investors own 54.32% of the company’s stock.

LENZ Therapeutics Trading Down 3.4 %

LENZ Therapeutics stock opened at $25.64 on Monday. The firm has a market capitalization of $706.20 million, a price-to-earnings ratio of -5.38 and a beta of 0.58. LENZ Therapeutics, Inc. has a 1-year low of $14.42 and a 1-year high of $38.93. The firm’s fifty day moving average price is $24.51 and its two-hundred day moving average price is $27.18.

LENZ Therapeutics (NASDAQ:LENZ) last released its quarterly earnings results on Wednesday, March 19th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.04). On average, research analysts forecast that LENZ Therapeutics, Inc. will post -2.18 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on LENZ. Citigroup raised their price target on shares of LENZ Therapeutics from $44.00 to $47.00 and gave the company a “buy” rating in a research note on Thursday, March 20th. TD Cowen began coverage on shares of LENZ Therapeutics in a research report on Tuesday, March 18th. They set a “buy” rating and a $60.00 price target on the stock. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $41.67.

LENZ Therapeutics Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.